Nasdaq
$9.33▼ 0.11%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $154.6MShares out 16.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 9.22After-hours26.09.23 05:094Ownership#●●●
SUTRO BIOPHARMA, INC.
Director Hans-Peter Gerber of Sutro Biopharma reported a change in beneficial ownership of company securities as of September 18, 2026. This filing serves as a standard disclosure regarding the adjustment of insider equity holdings.…more
$9.33-0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12Pre-market26.08.12 20:3010-QEarnings
SUTRO BIOPHARMA, INC.
Sutro Biopharma filed its 10-Q quarterly report for the period ending June 30, 2026, detailing ongoing collaboration and license agreements with key partners including Astellas, Ipsen, and Vaxcyte. The filing includes certifications from executive management confirming that the financial statements and internal controls fairly present the company's financial condition and operational results.…more
$9.33-0.11%vs prev closeView filingShare - 8.12Pre-market26.08.12 20:158-KKey event
SUTRO BIOPHARMA, INC.
Sutro Biopharma reported its Q2 2026 financial results and shared positive interim data from the Phase 1 trial of its oncology candidate, STRO-004. The drug demonstrated encouraging clinical activity and favorable tolerability in patients with pancreatic, head and neck, and non-small cell lung cancers, with the Phase 1 trial for STRO-006 scheduled to begin in Q3 2026. As of June 30, 2026, the company holds $164.3 million in cash and marketable securities, providing an operational runway into at least the second quarter of 2028.…more
$9.33-0.11%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.21 21:00#●●●#●●●#●●●
Sutro Biopharma Doses First Patient in Phase 1 Trial of STRO-006 for Solid Tumors…more
Sutro Biopharma has initiated the first patient dosing in its Phase 1 clinical trial for STRO-006, a next-generation ITGB6-targeting ADC. Initial clinical data from the study is expected to be released in the second half of 2027.…more
$9.33-0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUS